#USA #Cellipont Bioservices #Xiogenix #Ares X20 #The Woodlands, Texas

Cellipont Bioservices and Xiogenix: A Game-Changing Alliance

In the evolving landscape of biopharmaceutical manufacturing, a significant partnership has emerged between Cellipont Bioservices and Xiogenix. On December 10, 2024, both companies announced a collaboration that provides Cellipont clients with access to the innovative Ares™ X20 fill and finish system. This agreement is expected to greatly improve the efficiency and precision of cell therapy product filling processes for clients in the rapidly advancing field of cell and gene therapy.

The Ares™ X20 is not just any ordinary fill-and-finish system; it's at the forefront of biopharmaceutical technology. Designed to facilitate the production of cell and gene therapies, the Ares™ X20 system stands out due to its advanced features, including precise temperature control, automated formulation processes, and the ability to handle high throughput. Impressively, this system can process multiple containers in less than five minutes, drastically decreasing the time involved in production. Moreover, its design minimizes the presence of residual air and waste, ensuring that the formulations are not only high-quality but also consistent.

By incorporating the Ares™ X20 into their operations, Cellipont aims to enhance its manufacturing capabilities significantly. This state-of-the-art technology will allow them to scale operations more effectively, while also elevating safety and quality within their production processes. With the added capacity for automation, they can further adhere to the highest standards of quality and safety that their clients expect.

Darren Head, CEO of Cellipont Bioservices, expressed enthusiasm regarding this alliance, stating, "This partnership with Xiogenix marks another significant milestone for Cellipont Bioservices. We are committed to adopting advanced technologies that drive innovation and excellence in biopharmaceutical manufacturing. Through this collaboration, we can offer our clients enhanced service offerings and superior solutions."

The excitement is mutual at Xiogenix, as CEO Rachel Bahr remarked, "We are thrilled to join forces with Cellipont Bioservices to introduce our Ares™ X20 fill and finish system to more clients. This partnership aligns perfectly with our mission to deliver innovative solutions that improve the efficiency and reliability of biopharmaceutical manufacturing. We anticipate this collaboration will have a transformative impact on the industry."

About Cellipont Bioservices

Cellipont Bioservices is known as a leading Contract Development and Manufacturing Organization (CDMO) specializing in cell therapies. Their expert team is dedicated to providing comprehensive services ranging from process development to large-scale commercial manufacturing. Cellipont operates from a purpose-built facility, utilizing cutting-edge technology that enhances the overall quality of the cell therapies they manufacture. Their commitment to excellence ensures that they consistently meet and often surpass client expectations in delivering life-changing therapies to patients around the globe.

For more information about Cellipont Bioservices, visit their website at www.cellipont.com.

About Xiogenix

Xiogenix positions itself as a leader in biopharmaceutical technology, focused on providing solutions that elevate the quality and efficiency of biologics and therapy production. Their product range includes not only the advanced filling systems but also solutions for cold chain management and tissue processing systems, all essential for supporting the development of life-saving therapies. For further insights into their offerings, check out www.xiogenix.com.